# Carbamazepine — Drug Card

- **ChEMBL**: CHEMBL108
- **DrugCentral ID**: 489

## Primary target(s) (UniProt / HGNC)
> Use-dependent blockade of **voltage-gated sodium channels (Nav)**; representative α-subunits for mapping:
- **SCN1A / Nav1.1** — UniProt **P35498**; HGNC **10585**
- **SCN5A / Nav1.5** — UniProt **Q14524**; HGNC **10593**
- **SCN9A / Nav1.7** — UniProt **Q15858**; HGNC **10597**

## Candidate adverse events (prefer MedDRA PT; add HPO if useful)
- **Stevens–Johnson syndrome (SJS)** — MedDRA PT  
- **Toxic epidermal necrolysis (TEN)** — MedDRA PT  
- **Drug reaction with eosinophilia and systemic symptoms (DRESS)** — MedDRA PT  
- **Agranulocytosis** — MedDRA PT; HPO **HP:0001913**  
- **Aplastic anaemia** — MedDRA PT  
- **Hyponatraemia** — MedDRA PT; HPO **HP:0002902**  
- **Dizziness / Vertigo** — MedDRA PT; HPO **HP:0002321**  
- **Ataxia** — MedDRA PT; HPO **HP:0001251**  
- **Diplopia** — MedDRA PT; HPO **HP:0000651**

## CPIC pharmacogenomics highlights (gene / allele)
- **HLA-B*15:02** — strong association with **SJS/TEN**  
  - **Carbamazepine-naïve carriers**: **avoid carbamazepine** (and oxcarbazepine); use alternatives.  
  - If patient has tolerated CBZ for >3 months without cutaneous reaction, risk is lower but caution warranted.  
- **HLA-A*31:01** — associated with broader **CBZ hypersensitivity spectrum** (maculopapular eruption, DRESS, SJS/TEN)  
  - **Carriers**: consider **alternative therapy**; if CBZ is necessary, **start low and monitor closely**.
